In last trading session, Xeris Biopharma Holdings Inc (NASDAQ:XERS) saw 1.27 million shares changing hands with its beta currently measuring 1.82. Company’s recent per share price level of $2.56 trading at $0.15 or 6.02% at ring of the bell on the day assigns it a market valuation of $378.80M. That closing price of XERS’s stock is at a discount of -27.34% from its 52-week high price of $3.26 and is indicating a premium of 42.97% from its 52-week low price of $1.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.18 million shares which gives us an average trading volume of 1.32 million if we extend that period to 3-months.

For Xeris Biopharma Holdings Inc (XERS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information

Upright in the green during last session for gaining 6.02%, in the last five days XERS remained trading in the green while hitting it’s week-highest on Thursday, 07/25/24 when the stock touched $2.56 price level, adding 1.92% to its value on the day. Xeris Biopharma Holdings Inc’s shares saw a change of 8.72% in year-to-date performance and have moved 7.35% in past 5-day. Xeris Biopharma Holdings Inc (NASDAQ:XERS) showed a performance of 21.67% in past 30-days. Number of shares sold short was 11.41 million shares which calculate 9.66 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 4.75 to the stock, which implies a rise of 46.11% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6.5. It follows that stock’s current price would drop -17.19% in reaching the projected high whereas dropping to the targeted low would mean a loss of -17.19% for stock’s current value.

Xeris Biopharma Holdings Inc (XERS) estimates and forecasts

Statistics highlight that Xeris Biopharma Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 8.26% of value to its shares in past 6 months, showing an annual growth rate of 13.33% while that of industry is 13.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.13% during past 5 years.

XERS Dividends

Xeris Biopharma Holdings Inc is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders

Insiders are in possession of 2.69% of company’s total shares while institution are holding 41.94 percent of that, with stock having share float percentage of 43.09%. Investors also watch the number of corporate investors in a company very closely, which is 41.94% institutions for Xeris Biopharma Holdings Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at XERS for having 9.96 million shares of worth $22.01 million. And as of 2024-03-31, it was holding 7.2112 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 7.61 million shares on 2024-03-31. The number of shares represents firm’s hold over 5.5068 of outstanding shares, having a total worth of $16.81 million.